Role of human recombinant GM-CSF in the prevention and treatment of leukopenia with special reference to infectious diseases.
Recombinant human GM-CSF has been shown to be effective in reversing severe neutropenic states associated with the underlying disease or caused by cytotoxic drugs, and during engraftment after bone marrow transplantation. Preliminary evidence supports the view that restoration of adequate myelopoiesis results in better control of infection. The use of rhGM-CSF in special infectious diseases to activate cell function is currently being studied. Preliminary in vitro and in vivo data allow high expectations for the usefulness of rhGM-CSF in contributing to the control of these diseases.
Stern
A C
AC
Clinical Research Department, Sandoz Pharma, Basel, Switzerland.
Jones
T C
TC
D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D017053:Infection Control; D007970:Leukopenia / Q000517:prevention & control* / Q000628:therapy; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor